Role of molecular markers in breast cancer therapy

被引：0

作者：

Per Eystein Lnning ^{[1
,2
]}

机构：

[1] Section of Oncology,Institute of Medicine,University of Bergen

[2] Depart ment of Oncology,Haukeland University Hospital

来源：

中华乳腺病杂志(电子版) | 2010年 / 4卷 / 05期

关键词：

Breast neoplasms; Therapy; Prognostication; Prediction;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

<正>Translational research,in general,means to take knowledge from one area into a second.Traditional thought to represent transfer of knowledge from basic research into the clinic,translational research today covers a much broader term.Thus,most investigators will agree translational research covers a two-way process that also includes taking lessons from the clinic back to the laboratory,by which biological observations in vivo would create novel hypotheses to be further explored in laboratory experiments.

引用

页码：479 / 495

页数：17

共 20 条

[1]

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J] . Kathy S Albain,William E Barlow,Steven Shak,Gabriel N Hortobagyi,Robert B Livingston,I-Tien Yeh,Peter Ravdin,Roberto Bugarini,Frederick L Baehner,Nancy E Davidson,George W Sledge,Eric P Winer,Clifford Hudis,James N Ingle,Edith A Perez,Kathleen I Pritchard,Lois Shepherd,Julie

[2]

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial （NEAT/BR9601）[J] . John MS Bartlett,Alison F Munro,Janet A Dunn,Christopher McConkey,Sarah Jordan,Chris J Twelves,David A Cameron,Jeremy Thomas,Fiona M Campbell,Daniel W Rea,Elena Provenzano,Carlos Caldas,Paul Pharoah,Louise Hiller,Helena Earl,Christopher J Poole.Lancet Oncology . 2010 (3)

[3] Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 [J].

Junttila, Teemu T. ;

Akita, Robert W. ;

Parsons, Kathryn ;

Fields, Carter ;

Phillips, Gail D. Lewis ;

Friedman, Lori S. ;

Sampath, Deepak ;

Sliwkowski, Mark X. .

CANCER CELL, 2009, 15 (05) :429-440

[4]

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study[J] . Bella Kaufman,Maureen Trudeau,Ahmad Awada,Kimberly Blackwell,Thomas Bachelot,Vanessa Salazar,Michelle DeSilvio,Ronald Westlund,Tal Zaks,Neil Spector,Stephen Johnston.Lancet Oncology . 2009 (6)

[5] Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer [J].

Rhiem, K. ;

Wappenschmidt, B. ;

Bosse, K. ;

Koeppler, H. ;

Tutt, A. N. ;

Schmutzler, R. K. .

CLINICAL ONCOLOGY, 2009, 21 (06) :448-450

[6] The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer [J].

Straver, Marieke E. ;

Glas, Annuska M. ;

Hannemann, Juliane ;

Wesseling, Jelle ;

van de Vijver, Marc J. ;

Rutgers, Emiel J. Th. ;

Peeters, Marie-Jeanne T. F. D. Vrancken ;

van Tinteren, Harm ;

van't Veer, Laura J. ;

Rodenhuis, Sjoerd .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) :551-558

[7] Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy [J].

Yonemori, Kan ;

Tsuta, Koji ;

Shimizu, Chikako ;

Hatanaka, Yutaka ;

Hashizume, Kaoru ;

Ono, Makiko ;

Kouno, Tsutomu ;

Ando, Masashi ;

Tamura, Kenji ;

Katsumata, Noriyuki ;

Hasegawa, Tadashi ;

Kinoshita, Takayuki ;

Fujiwara, Yasuhiro .

MEDICAL ONCOLOGY, 2009, 26 (03) :344-349

[8] Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients [J].

Byrski, T. ;

Huzarski, T. ;

Dent, R. ;

Gronwald, J. ;

Zuziak, D. ;

Cybulski, C. ;

Kladny, J. ;

Gorski, B. ;

Lubinski, J. ;

Narod, S. A. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :359-363

[9]

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial[J] . Birgitte B Rasmussen,Meredith M Regan,Anne E Lykkesfeldt,Patrizia Dell’Orto,Barbara Del Curto,Katrine L Henriksen,Mauro G Mastropasqua,Karen N Price,Eliane Méry,Magali Lacroix-Triki,Stephen Braye,Hans J Altermatt,Richard D Gelber,Monica Castiglione-Gertsch,Aron Goldhirsch,Barry A Gust

[10] The molecular pathology of hereditary breast cancer [J].

Palacios, J. ;

Robles-Frias, M. J. ;

Castilla, M. A. ;

Lopez-Garcia, M. A. ;

Benitez, J. .

PATHOBIOLOGY, 2008, 75 (02) :85-94

← 1 2 →